MelatoninvsPhenibut

Melatonin binds to G-protein-coupled MT1 and MT2 receptors, which are densely expressed in the suprachiasmatic nucleus (SCN) of the hypothalamus—the brain's master circadian pacemaker. MT1 activation couples to Gi/o proteins, inhibiting adenylyl cyclase and reducing cAMP, which suppresses SCN neuronal firing and promotes sleepiness. MT2 activation modulates cGMP signaling and phase-shifts the circadian rhythm (useful for jet lag and shift work). Melatonin also has direct antioxidant properties, scavenging hydroxyl and peroxyl radicals in mitochondria and upregulating antioxidant enzymes like glutathione peroxidase. It supports immune function through modulation of T-cell cytokine production and may act at MT3 (quinone reductase 2) binding sites. Low doses are often more effective because they mimic physiological nighttime levels.

Phenibut is a structural analog of GABA with a phenyl ring that confers lipophilicity and allows blood-brain barrier penetration (unlike GABA itself). It acts as a GABA-B receptor agonist, binding to the GABAB1/GABAB2 heterodimer and activating Gi/o-coupled signaling (similar to baclofen), producing anxiolytic, muscle relaxant, and sedative effects through inhibition of adenylyl cyclase and modulation of potassium and calcium channels. Phenibut also blocks the alpha-2-delta-1 and alpha-2-delta-2 subunits of voltage-gated calcium channels, reducing presynaptic calcium influx and neurotransmitter release (similar to gabapentin/pregabalin). The dual mechanism—GABA-B agonism dampening inhibitory interneurons and calcium channel blockade reducing excitatory transmission—produces potent anti-anxiety and sleep-promoting effects. Rapid tolerance develops due to receptor downregulation.